Abstract 311P
Background
Thyroid cancer is the most common endocrine-related malignancy in the Philippines. It ranks seventh overall based on the latest Department of Health statistics. Its incidence increases every year, noted especially in females and in the reproductive age group. This study determined the incidence and the profile of all thyroid carcinomas encountered in a tertiary teaching hospital in the Philippines.
Methods
Data were collected from the University of Santo Tomas Hospital in 2015 to 2018 from different specialties, including the Pathology Department. All information gathered were kept confidential in respect to the data privacy act.
Results
A total of 1618 thyroid specimens were sent for histopathologic examination from 2015-2018 and 35.6% (n = 576) of these were malignant. Fine needle aspiration was the most frequent form of biopsy done. Eight hundred eighty patients underwent thyroidectomy and 43% (n = 378) of them had malignancy based on final histopathology. Eighty one percent (81%) were females and 19% were males. The most common type of malignancy was papillary thyroid carcinoma (74.6%), followed by papillary microcarcinoma (18.4%), follicular carcinoma (4.8%), anaplastic carcinoma (0.7%), squamous cell (0.7%) and poorly differentiated carcinoma (0.9%). The most frequent subtype of papillary carcinoma seen was the conventional type (31.7%). Majority of the patients had no extrathyroidal extension (41%), no lymphovascular invasion (38%), had clear margins (70%) and had no lymph node involvement (21%). Of the patients diagnosed with papillary and follicular carcinoma and papillary microcarcinoma, 30% underwent RAI in the same institution. There were 17 patients who underwent radiation therapy, mostly for palliative intent because of RAI-refractory disease. There was one case who underwent concurrent chemoradiation for anaplastic thyroid carcinoma.
Conclusions
This study showed that one-third of thyroid specimens received in the institution turned out to be malignant, with papillary carcinoma still the most frequent type. Total thyroidectomy is the most common form of curative surgery done.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
27P - The prognostic value of neutrophil to lymphocyte ratio (NLR) and 18F-FDG PET SUV in breast cancer patients underwent neoadjuvant chemotherapy
Presenter: Soong June Bae
Session: Poster display session
Resources:
Abstract
28P - Accuracy of core biopsy in predicting pathologic complete response in the breast in patients with complete/near complete clinical and radiological response (Complete Responders in the Breast – CRBr): A feasibility study
Presenter: Nisha Hariharan
Session: Poster display session
Resources:
Abstract
29P - Tumour response to neoadjuvant chemotherapy in breast cancer: Routine pathologic markers improve the predictive power of a cell-loss metric based on release of thymidine kinase 1 into blood
Presenter: Bernhard Tribukait
Session: Poster display session
Resources:
Abstract
30P - Comparison of metabolic changes between neoadjuvant chemotherapy and neoadjuvant endocrine therapy in premenopausal women with ER positive, HER2 negative breast cancer
Presenter: Ho-hyun Ryu
Session: Poster display session
Resources:
Abstract
31P - Circulating miR-155 as a potential therapeutic monitoring marker in breast cancer
Presenter: Sumadi Lukman Anwar
Session: Poster display session
Resources:
Abstract
32P - Profile of breast cancer epidemiology in Sanglah General Hospital, Denpasar, Bali from 2012 to 2019
Presenter: Citra Aryanti
Session: Poster display session
Resources:
Abstract
33P - Contrast enhanced chest CT in patients with breast cancer: Comprehensive imaging analysis and correlation with biological markers
Presenter: Bo Hwa Choi
Session: Poster display session
Resources:
Abstract
34P - Verification of metabolic regulatory mechanisms in androgen receptor-positive triple negative breast cancer
Presenter: Yuka Asano
Session: Poster display session
Resources:
Abstract
35TiP - Ribociclib plus goserelin with hormonal therapy versus physician choice chemotherapy in pre-/perimenopausal patients with HR+, HER2– inoperable locally advanced breast cancer (ABC): RIGHT choice study
Presenter: Yen-Shen Lu
Session: Poster display session
Resources:
Abstract
36TiP - A prospective study to assess response to neoadjuvant hormonal therapy in postmenopausal women with hormone-receptor positive breast cancer at a regional cancer centre in South India
Presenter: Shina Goyal
Session: Poster display session
Resources:
Abstract